LATEST UPDATES » Vol 26, Nos. 09 & 10, September & October 2022 – Toxins and Medicines – Two Sides of the Same Coin       » Utilising Metal Nanoparticles as Plant Growth Regulators to Improve Crop Yield       » Remedy or Poison? How Microplastics Influence Copper Ion Toxicity in Aquatic Plants       » Synthesising Schiff Base Antimicrobial Copper Complexes With Unprecedented Speed       » Enhancing the Understanding of Past Infections With Machine Learning       » Mini, Cellular Bioweapons: Understanding the Structure and Mechanism of Stinging in Sea Anemone Nematocysts       » Converting Dead Spiders Into Gripping Tools
Vol 26, Nos. 07 & 08, July & August 2022   |   Issue PDF view/purchase
GE Healthcare and National Cancer Centre Singapore Collaborate on AI-Driven Research to Improve Cancer Care
The collaboration is the first of its kind for GE Healthcare in the Asia-Pacific region and will focus on how artificial intelligence (AI) driven research can be used to improve cancer care.

GE Healthcare announced in June a new collaboration with National Cancer Centre Singapore (NCCS), which focuses on how artificial intelligence (AI) driven research can be used to improve cancer care. The collaboration is the first of its kind for GE Healthcare in the Asia-Pacific (APAC) region and aims to spur the potential for more tailored treatment options for specific cancer types and offer the potential to evaluate clinically significant information along the patient journey for a provider’s efficient decision making, leveraging on AI and text processing.

In 2020, there were an estimated 19 million new cancer cases in the world, with 9.7 million or 50 per cent of them in the Asia-Pacific, according to Globocan. The agreement between GE Healthcare and NCCS will see the two organisations collaborate on new AI-powered solutions for data analytics and clinical workflows that support care for cancer patients in this part of the world—combining GE Healthcare’s imaging and monitoring expertise with NCCS’s deep expertise in research and development, testing, and consultation.

“NCCS is one of the region’s leading centres of excellence for cancer research and treatment, and GE Healthcare is committed to supporting them in driving the transformation and advancement of cancer care pathways in Singapore and beyond. This collaboration is an important step forward in our commitment to enabling precision health through digital technology that simplifies healthcare providers’ decision-making, accelerates care delivery and has the potential to improve patient outcomes,” said Elie Chaillot, President & CEO Intercontinental at GE Healthcare.

“This new collaboration with NCCS is GE Healthcare’s first in the Asia-Pacific region that leverages AIpowered research to improve precision health practices for cancer care. Simplifying the way data is managed can help healthcare professionals improve patient outcomes with faster decision making and more precise treatment options,” said Dr. Ben Newton, General Manager Oncology at GE Healthcare.

“The National Cancer Centre Singapore continually engages the latest digital innovations to improve the delivery of cancer care for our patients. This collaboration combines the strengths of our clinical perspective and deep expertise in oncology care, analytics and translational research with GE Healthcare’s global reach, innovative technologies and services. Working together, we hope to leverage next-generation digital tools to enhance [the] integration of cross-disciplinary information, augment clinical decision making and improve outcomes for our patients,” said Associate Professor Iain Tan, Senior Consultant and Director of Research, Division of Medical Oncology, National Cancer Centre Singapore, and Principal Investigator for this collaboration.

Source: GE Healthcare

What Has Covid Ever Done for Us?
news 2022 PDA Aseptic Processing of Biopharmaceuticals Conference
news Thailand LAB INTERNATIONAL, Bio Asia Pacific, and FutureCHEM INTERNATIONAL are ready to offer the Science and Technology Industry complete solutions this September!
news Better together: registration opens for Vitafoods Asia 2022 co-located with Fi Asia in October
news 2022 PDA Pharmaceutical Manufacturing & Quality Conference

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   [email protected] or Ms Carmen Chan
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   [email protected]
Copyright© 2022 World Scientific Publishing Co Pte Ltd  •  Privacy Policy